Apellis Pharmaceuticals, Inc. (APLS) Surged to $30.33

April 16, 2018 - By Sarah North

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) rose significantly to $30.33. On Apr, 16 it was posted by Barchart.com. Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) has $1.53 billion MC. The company’s valuation will be $122.24M more at $32.75 price target.

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases.The firm is valued at $1.53 billion. The Company’s lead product candidates include APL-2 and APL-1, to treat paroxysmal nocturnal hemoglobinuria, geographic atrophy, intermediate age-related macular degeneration, and chronic obstructive pulmonary disease.Last it reported negative earnings. The firm develops APL-2 for subcutaneous injection, which is an injection into the tissue under the skin, and for intravitreal injection that is an injection into the eye, as well as APL-1 for inhaled administration.

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.